Literature DB >> 32213020

Natural history, diagnosis and treatment approach to fibrostenosing Crohn's disease.

Sara El Ouali1, Benjamin Click1, Stefan D Holubar2, Florian Rieder1,3.   

Abstract

Stricturing Crohn's disease (CD) is a significant clinical problem. The presence of a stricture may be suggested by clinical symptoms. Cross-sectional imaging using computed tomography or magnetic resonance enterography is essential in diagnosing strictures as it allows further characterization and evaluation for complications such as abscess, fistulizing disease or malignancy. Managing small bowel stricturing CD should be approached in a multidisciplinary fashion. Medical therapy can be considered in strictures which are not associated with complications, with most of the data supporting anti-TNF strategies in this setting. If the disease is refractory to medical therapy, endoscopic therapy or surgery should be performed. Endoscopic balloon dilation (EBD) is an option for short, uncomplicated and straight strictures that are within reach of a colonoscope. Although EBD has good short-term outcomes, repeat dilation is often required. Surgical options mainly include resection and strictureplasty. Strictures refractory to medical therapy, not amenable or refractory to EBD, or associated with complications or malignancy should be managed surgically. However, surgery may also be considered at an earlier stage depending on disease characteristics and patient preference. Postoperative recurrence is common, highlighting the importance of careful monitoring of the patient postoperatively and optimization of medical management accordingly. There is a pressing need to develop anti-fibrotics for the treatment of stricturing CD. This requires the development of standardized diagnostic criteria, patient-reported outcome measures and validation of endpoints in fibrostenotic CD. The STAR consortium is pioneering this effort in order to allow development and testing of anti-fibrotics in future clinical trials.

Entities:  

Keywords:  Crohn’s disease; Stricture; endoscopic balloon dilation; fibrosis; inflammatory bowel disease; stenosis; surgery

Mesh:

Substances:

Year:  2020        PMID: 32213020      PMCID: PMC7184664          DOI: 10.1177/2050640620901960

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  50 in total

1.  The presence of fistulas and NOD2 homozygosity strongly predict intestinal stenosis in Crohn's disease independent of the IL23R genotype.

Authors:  Matthias Jürgens; Stephan Brand; Rüdiger P Laubender; Julia Seiderer; Jürgen Glas; Martin Wetzke; Johanna Wagner; Simone Pfennig; Cornelia Tillack; Florian Beigel; Maria Weidinger; Fabian Schnitzler; Martin E Kreis; Burkhard Göke; Peter Lohse; Karin Herrmann; Thomas Ochsenkühn
Journal:  J Gastroenterol       Date:  2010-04-29       Impact factor: 7.527

2.  Detection of Dysplasia or Cancer in 3.5% of Patients With Inflammatory Bowel Disease and Colonic Strictures.

Authors:  Mathurin Fumery; Guillaume Pineton de Chambrun; Carmen Stefanescu; Anthony Buisson; Aude Bressenot; Laurent Beaugerie; Aurelien Amiot; Romain Altwegg; Guillaume Savoye; Vered Abitbol; Guillaume Bouguen; Marion Simon; Jean-Pierre Duffas; Xavier Hébuterne; Stéphane Nancey; Xavier Roblin; Emmanuelle Leteurtre; Gilles Bommelaer; Jeremie H Lefevre; Francesco Brunetti; Françoise Guillon; Yoram Bouhnik; Laurent Peyrin-Biroulet
Journal:  Clin Gastroenterol Hepatol       Date:  2015-05-19       Impact factor: 11.382

3.  Efficacy of tumour necrosis factor antagonists in stricturing Crohn's disease: A tertiary center real-life experience.

Authors:  Mariangela Allocca; Cristiana Bonifacio; Gionata Fiorino; Antonino Spinelli; Federica Furfaro; Luca Balzarini; Stefanos Bonovas; Silvio Danese
Journal:  Dig Liver Dis       Date:  2017-03-30       Impact factor: 4.088

4.  Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease.

Authors:  E Louis; A Collard; A F Oger; E Degroote; F A Aboul Nasr El Yafi; J Belaiche
Journal:  Gut       Date:  2001-12       Impact factor: 23.059

5.  Is early limited surgery associated with a more benign disease course in Crohn's disease?

Authors:  Petra Anna Golovics; Laszlo Lakatos; Attila Nagy; Tunde Pandur; Istvan Szita; Mihaly Balogh; Csaba Molnar; Erzsebet Komaromi; Barbara Dorottya Lovasz; Michael Mandel; Gabor Veres; Lajos S Kiss; Zsuzsanna Vegh; Peter Laszlo Lakatos
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

6.  Small bowel stenosis in Crohn's disease: clinical, biochemical and ultrasonographic evaluation of histological features.

Authors:  G Maconi; L Carsana; P Fociani; G M Sampietro; S Ardizzone; M Cristaldi; F Parente; G L Vago; A M Taschieri; G Bianchi Porro
Journal:  Aliment Pharmacol Ther       Date:  2003-10-01       Impact factor: 8.171

7.  Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD.

Authors:  Marco Daperno; Geert D'Haens; Gert Van Assche; Filip Baert; Philippe Bulois; Vincent Maunoury; Raffaello Sostegni; Rodolfo Rocca; Angelo Pera; Annemie Gevers; Jean-Yves Mary; Jean-Frédéric Colombel; Paul Rutgeerts
Journal:  Gastrointest Endosc       Date:  2004-10       Impact factor: 9.427

8.  Long-term follow-up of patients with Crohn's disease. Relationship between the clinical pattern and prognosis.

Authors:  R G Farmer; G Whelan; V W Fazio
Journal:  Gastroenterology       Date:  1985-06       Impact factor: 22.682

9.  Small bowel resection rates in Crohn's disease and the indication for surgery over time: experience from a large tertiary care center.

Authors:  Mark Lazarev; Thomas Ullman; Wolfgang H Schraut; Kevin E Kip; Melissa Saul; Miguel Regueiro
Journal:  Inflamm Bowel Dis       Date:  2010-05       Impact factor: 5.325

10.  Azathioprine is more effective than mesalazine at preventing recurrent bowel obstruction in patients with ileocecal Crohn's disease.

Authors:  Fernando Mendonça Vidigal; Gláucio Silva de Souza; Liliana Andrade Chebli; Tarsila Campanha da Rocha Ribeiro; Maria Cristina Vasconcellos Furtado; Antonio Carlos Santana Castro; André Luis Tavares Pinto; Bruno do Valle Pinheiro; Fabio Heleno de Lima Pace; Juliano Machado de Oliveira; Karine Andrade de Oliveira Zanini; Pedro Duarte Gaburri; Alexandre Zanini; Luiz Cláudio Ribeiro; Julio Maria Fonseca Chebli
Journal:  Med Sci Monit       Date:  2014-11-05
View more
  3 in total

Review 1.  Therapeutic Drug Monitoring of Biologics in IBD: Essentials for the Surgical Patient.

Authors:  Rodrigo Bremer Nones; Phillip R Fleshner; Natalia Sousa Freitas Queiroz; Adam S Cheifetz; Antonino Spinelli; Silvio Danese; Laurent Peyrin-Biroulet; Konstantinos Papamichael; Paulo Gustavo Kotze
Journal:  J Clin Med       Date:  2021-11-29       Impact factor: 4.241

Review 2.  Multi-utility of therapeutic drug monitoring in inflammatory bowel diseases.

Authors:  Camilla de Almeida Martins; Karoline Soares Garcia; Natália Sousa Freita Queiroz
Journal:  Front Med (Lausanne)       Date:  2022-07-28

Review 3.  Prevention and Treatment of Stricturing Crohn's Disease - Perspectives and Challenges.

Authors:  Joseph Sleiman; Sara El Ouali; Taha Qazi; Benjamin Cohen; Scott R Steele; Mark E Baker; Florian Rieder
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2020-12-28       Impact factor: 3.869

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.